secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009894
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre appoints CCO, accelerates SPY001 readout to Q2; six proof-of-concept reads expected in 2026
--------------------------------------------------------------------------------

- Appointed Kate Tansey Chevlen as CCO; previously Amgen VP, Global Marketing Head for Immunology.
- SPY001 enrollment complete ahead of schedule; SKYLINE Part A readouts now expected to begin Q2 2026.
- Six total proof-of-concept readouts planned: 3 from SKYLINE (UC) and 3 from SKYWAY (RA, PsA, axSpA) by 4Q 2026.
- Pro forma cash $783M as of Sept 30, 2025, including Oct 2025 offering net proceeds; runway into H2 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312526009894/0001193125-26-009894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312526009894/d28401d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer